


SARS-CoV-2 Sequencing Update **3 December 2021**



Prepared by the National Institute for Communicable Diseases (NICD) of the National Health Laboratory (NHLS) on behalf of the Network for Genomics Surveillance in South Africa (NGS-SA)

Department

cience and Innovation REPUBLIC OF SOUTH AFRICA The genomic data presented here are based on South African SARS-CoV-2 sequence data downloaded from GISAID (www.gisaid.org) on 3 December at 08h30




Data license: https://www.gisaid.org/registration/terms-of-use/


Elbe, S., and Buckland-Merrett, G. (2017) Data, disease and diplomacy: GISAID's innovative contribution to global health. Global Challenges, 1:33-46. DOI: 10.1002/gch2.1018 PMCID: 31565258 Shu, Y., McCauley, J. (2017) GISAID: Global initiative on sharing all influenza data – from vision to reality. EuroSurveillance, 22(13) DOI: 10.2807/1560-7917.ES.2017.22.13.30494 PMCID: PMC5388101

Case data is based on specimen collection date. Cases from <u>https://www.nicd.ac.za/diseases-a-z-index/disease-index-covid-19/surveillance-reports/weekly-epidemiological-brief/</u> Test data from <u>https://www.nicd.ac.za/diseases-a-z-index/disease-index-covid-19/surveillance-reports/weekly-testing-summary/</u>

Number of South African genomes deposited on GISAID, by specimen collection week, 2020 and 2021 (N=24 189*)




GISAID genomes vs total cases, 2020 and 2021 (N=24 189)



All provinces, apart from GP, KZN, NC and WC, have comparable percentage of overall cases and overall sequenced genomes. The majority of November sequencing data is from Gauteng.




Omicron lineage mutation profile



- 45-52 amino acid changes (including deletions) across the whole GENOME
 - 26-32 changes in SPIKE
- Does <u>not possess</u> the RdRp G671S change associated with a decrease in Ct value for Delta variants
- Does possess the Δ69-70, which causes the S-Gene Target Failure (SGTF) and was
 previously seen in the Alpha VOC



Omicron spike mutations compared to other VOC/VOIs




- Multiple changes within the two immunogenic regions in S1 (NTD and RBD)
 - including a three amino acid insertion
- Accumulation of mutations surrounding the furin cleavage site
 - Including combination of N679K and P681H
- Effect of most spike S2 subunit changes have not been defined, but may be linked to immune escape




Mutational profile of Omicron sequences

Frequency of Spike SNVs for Omicron (n = 404)



Frequency of whole genome SNVs for Omicron (n = 404)




Mutational profile of Omicron is largely shared amongst all sequences




Omicron global prevalence

Detection of Omicron Globally (countries = 28; n = 404)




Number of Omicron Genomes



Omicron has been detected in 28 countries across the globe (detections based on GISAID).




Proportion and number of clades by epiweek in South Africa, 2021 (N= 17 813)



Delta dominated South Africa's third wave with >80% frequency in October, with C.1.2 detection remaining <4%. Omicron appears to dominate November sequencing data but sequencing is ongoing to determine its true prevalence.






Surveillance in South Africa

Omicron was first detected in South Africa in November, comprising 73% (228/312) of sequences.

Detection Rates: Beta, Delta, C.1.2 and Omicron

Detection rates of variants being monitored in South Africa




C.1.2 has been detected at \leq 4% of sequences monthly.

Beta increased in prevalence in October but has not been detected in November.

Omicron first detected in South Africa on November 8th accounting for 73% (n=228/312) genomes from this month.




Eastern Cape Province, 2021, n =1673




NGS-SA Network for Genomic Surveillance in South Africa

Free State Province, 2021, n = 1013






Gauteng Province, 2021, n = 4797






KwaZulu-Natal Province, 2021, n = 2159






Limpopo Province, 2021, n = 1133






Mpumalanga Province, 2021, n = 1064






Northern Cape Province, 2021, n = 1202






North West Province, 2021, n = 1152





Western Cape Province, 2021, n =3537






Summary

- New B.1.1.529 (21K) lineage has been designated Variant of Concern Omicron
 - Current earliest detection in South Africa: 8 November, Gauteng
 - Omicron dominates November sequencing data at 73% of genomes (n=228/312). Sequencing is ongoing to determine prevalence of Omicron in other provinces.
 - Omicron has now been detected in 28 countries worldwide
 - More information can be found at https://www.nicd.ac.za/frequently-asked-questions-for-the-b-1-1-529-mutated-sars-cov-2-lineage-in-south-africa/
- Delta variant dominated in all provinces until end October
 - The Delta sub-lineages vary by province
- C.1.2 lineage detected in all provinces of South Africa with prevalence of <4% of genomes per month







ABORATONAL HEALTH

University of Stellenbosch & NHLS Tygerberg Virology



Susan Engelbrecht Wolfgang Preiser Gert van Zyl Tongai Maponga Bronwyn Kleinhans Shannon Wilson Karabo Phadu Tania Stander Kamela Mahlakwane Mathilda Claassen Diagnostic laboratory staff

MA

EDCTP

W

Same

CAPE TOWN HYTN

cence - innovation

IN AT THE INCOME. AND AND

University of Cape Town, NHLS & WCG

👽 health



NHLS-UCT

Diana Hardie

Kruger Marais

WCG-UCT Carolyn Williamson Mary-Anne Davies Nei-yuan Hsiao

Hannah Hussey Andrew Boulle Masudah Paleker Theuns Jacobs Stephen Korsman Erna Morden Ziyaad Valley-Omar





Robert Wilkinson Darren Martin Nicola Mulder Wendy Burgers Ntobeko Ntusi Rageema Joseph Sean Wasserman Linda Boloko

Zoonotic arbo and respiratory virus program Centre for Viral Zoonoses Department Medical Virology/ NHLS Tshwane Academic division University of Pretoria

9

ZARV research program/UP Marietjie Venter (Head: ZARV) Adriano Mendes (Postdoc) Amy Strydom (Postdoc) Michaela Davis (MSc, intern medical scientist)

NHLS Tshwane Prof Simnikiwe Mayaphi (HOD)

Funders:

GIZ/BMBF: African Network for Improved diagnostics and epidemiology of common and emerging infectious agents (ANDEMIA) G7 Global Health fund, Robert Koch Institute, Dr Fabian Leendertz

UKZN-Inkosi Albert Luthuli **Central Hospital**



Dr Khanyi Msomi Dr Pravi Moodley Dr Aabida Khan Dr Lili Gounder Dr Kerri Francois Dr Cherise Naicker Dr Joedene Chetty

KWAZULU-NATAL VAKWAZULU-NATALI

Dr Neli Ngcaba Dr Kerusha Govender Dr Tshepiso Mosito Mr Malcolm Ellapen Mr Kubendran Reddy The COVID-19 Bench team

University of KwaZulu-Natal & Africa Health Research Institute



Tulio de Oliveira Richard Lessels Houriivah Tegally Eduan Wilkinson Jennifer Giandhari Sureshnee Pillav Emmanuel James San

KRISP at UKZN:



National Institute for Communicable Diseases


NICD SARS-CoV-2 Sequencing

Group

AFRICA CDC



Centre for Respiratory Diseases & Meningitis Jinal Bhiman Anne von Gottberg Cathrine Scheepers Thabo Mohale Constantinos Kurt Wibmer Daniel Amoako Thandeka Moyo Josie Everatt Tandile Hermanus Boitshoko Mahlangu Frances Ayres Noxolo Ntuli Zanele Molaudzi Anele Mnguni Bronwen Lambson Amelia Buys Tandile Hermanus Cardia Fourie Mashudu Madzivhandila Noluthando Duma Prudence Kgagudi Linda de Gouveia Brent Oosthuysen Penny Moore Lynn Morris NICD Groups





Cheryl Cohen

Centre for HIV and STIs Sequencing Core Facility Zamantungwa Khumalo

Annie Chan Morne du Plessis Stanford Kwenda Phillip Senzo Mtshali Mushal Allam Florah Mnyameni Arshad Ismail









University of the Free State



UFS

Dominique Goedhals Armand Bester Martin Myaga Peter Mwangi Emmanuel Ogunbayo Milton Mogotsi Makgotso Maotoana Lutfiyya Mohamed

NHLS Division of Virology

Diagnostic laboratory staff

Sabeehah Vawda

Thokozani Mkhize

Felicity Burt











Key to Disgnostic Excellence

AMPATH

LABORATORIES

1

PathCare

Vermaak

FIOCRUZ

africa

NHLS Koeleka Mlisana Zinhle Makatini Eugene Elliot Florette K. Treurnicht Kathleen Subramoney Oluwakemi Laguda-Akingba Shareef Abrahams Greta Hoyland Gloria Selabe Elias Bereda

Jeannette Wadula

Hyrax Biosciences Simon Travers

Cape Town HVTN Laboratory Erica Anderson-Nissen Anneta Naidoo

Ndlovu Research **Hugo Tempelman** CJ Umunnakwe

Lancet Allison J. Glass **Raquel Viana**

Ampath Terry Marshall **Cindy van Deventer** Eddie Silberbauer

Pathcare Vermaak Andries Drever Howard Newman **Riaan Writes** Marianne Wolfaardt Warren Lowman

Bridge-the-Gap Raymond Rott

Cytespace Africa Laboratories Christa Viljoen

ARC-OVI Lia Rotherham CAPRISA Salim Abdool Karim Nigel Garret

Additional support and collaborators

UKZN - Big Data Francesco Pettruccione Ilya Sinayskiy

University of Oxford José Lourenço

FioCruz, Brazil Vagner Fonseca Marta Giovanetti Luiz Carlos Junior Alcantara Africa CDC John Nkengasong Sofonias Tessema

Netcare: **Richard Friedland** Craig Murphy Caroline Maslo Liza Sitharam

DSI

Glaudina Loots

SA MRC **Glenda Gray**


















South African genomes submitted per submitting lab, 2020 and 2021 (N=24 189)



NGS-SA Labs CERI: Centre for Epidemic Response and Innovation KRISP: KZN Research Innovation and Sequencing Platform NICD: National Institute for Communicable Diseases NHLS: National Health Laboratory Service SU: Stellenbosch University UCT: University of Cape Town UFS: University of the Free State UP: University of Pretoria *NGS-SA laboratories

Multiple labs from NGS-SA and collaborating private laboratories are contributing to the sequencing effort.



Variants of Concern (VOC)

WHO label	Pango lineages+	GISAID clade	Nextstrain clade	Additional amino acid changes monitored*	Earliest documented samples	Date of designation
Alpha	B.1.1.7 [#]	GRY	20I (V1)	+S:484K +S:452R	United Kingdom, Sep-2020	18-Dec-2020
Beta	B.1.351	GH/501Y.V2	20H (V2)	+S:L18F	South Africa, May-2020	18-Dec-2020
Gamma	P.1	GR/501Y.V3	20J (V3)	+S:681H	Brazil, Nov-2020	11-Jan-2021
Delta	B.1.617.2§	G/478K.V1	21A	+S:417N	India, Oct-2020	VOI: 4-Apr-2021 VOC: 11-May-2021
Omicron*	B.1.1.529	GR/484A	21K	_	Multiple countries, Nov-2021	VUM: 24-Nov-2021 VOC: 26-Nov-2021

https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/ accessed 3 December 2021

*Notable spike (S) amino acid changes under monitoring, which are currently reported in a minority of sequenced samples *Includes all descendant lineages.

[#]Includes all Q.* lineages in the PANGO nomenclature system.

[§]Includes all AY.* lineages in the PANGO nomenclature system.

Currently designated Variants of Interest (VOI)

WHO label	Pango [*] lineages	GISAID clade	Nextstrain clade	Earliest documented samples	Date of designation
Lambda	C.37	GR/452Q.V1	21G	Peru, Dec-2020	14-Jun-2021
Mu	B.1.631	GH	21H	Colombia, Jan-2021	30-Aug-2021

https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/ accessed December 2021

^{*}Includes all descendant lineages.

Submission of routine specimens for sequencing

- representative of multiple geographic regions (provinces/districts/health facilities) from individuals of
 - all ages
 - over as many time periods during the SARS-CoV-2 epidemic in South Africa
- requested that testing laboratories in both the private and public sectors, submit respiratory samples to their closest NGS-SA sequencing laboratory on a routine basis (ideally every week) as follows, depending on the capacity of the testing laboratory:
 - All positives samples should be sent every week (NGS-SA laboratory will perform random sampling as described below) OR
 - A weekly selection of approximately 10%-20% of randomly selected positive samples should be sent every week. Number of selected samples will depend on the size of laboratory and how many other laboratories are drained by the submitting laboratory.

Submission of special interest specimens for sequencing

In addition to routine samples mentioned above, please send specimens separately to above and clearly marked if:

- Suspected vaccine breakthrough (≥14 days after vaccine), especially if hospitalised and clinically severe
- Suspected re-infection (≥90 days after previous episode), especially if hospitalised and clinically severe
- Prolonged shedding with high SARS-CoV-2 viral loads (i.e. Ct values less than 30 for more than 1 month post-primary diagnosis) in immunocompromised individuals
- Possible animal-to-human transmission
- Suspected cases of importation from another country, especially countries known to harbour SARS-CoV-2 variants of concern or countries with little available information
- Clusters of "unusual" cases (e.g., in terms of disease presentation, patient groups affected, etc.)